Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +9.875p +5.36% 194.00p 192.75p 194.00p 200.00p 185.00p 185.00p 135,891 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -10.4 -12.1 - 135.78

Silence Therapeutics Share Discussion Threads

Showing 50226 to 50249 of 50250 messages
Chat Pages: 2010  2009  2008  2007  2006  2005  2004  2003  2002  2001  2000  1999  Older
DateSubjectAuthorDiscuss
22/9/2017
20:52
Good call on Woodford, djnzloop. So with Woodford below the notifiable threshold, I think the major shareholders, with total positions including derivatives, are now: 29.2% Richard Griffiths 20.6% Robert Keith 11.9% Invesco (from Annual Report) 7.7% Henderson (from Annual Report) 5.3% ING 5.3% Aviva That's 80% held between the top 6 investors, with another 2.8% held by Ali (according to annual report). Is it credible that ING is holding that position for its own account, or is it likely to be on behalf of a client or as the underlying asset for a derivative offered to a client?
1gw
22/9/2017
18:59
The more held in just a few hands the better. Liquidity is going to be at a premium so any whiff of a deal and this is going to squeeze like buggary
rogen83
22/9/2017
16:02
Griffiths & Keith now own near 50% - the picture is complete and once more, an absolute work of art to watch.
richie666
22/9/2017
15:27
Robert Keith up as well.
1gw
22/9/2017
14:21
So Aviva sold down on Wednesday but ING and more interestingly Richard Griffiths increased their holdings. Reassuring to see RG increasing as he has held for long time, and especially reassuring that the increase is all to "Richard Griffiths & Family" rather than one of his subsidiary companies. If he still sees value adding at these levels, that is good enough for me.
callumross
22/9/2017
09:42
callumross - I don't think the £8.56m is materially inaccurate, just a bit confusing. They are quoting the book value at 30th June, where "available for sale financial assets" were in the accounts at £8.555m. However, I do think the "up over 200%" is inaccurate. Silence purchased the stake at an average price of $1.65, so at a current price of about $3.50, the increase is $1.85, which is an increase of 112%, so the stake in $ terms is up over 100% since purchase, not over 200%. "That capitalises the business still at just £133 million with the valuation being backed by net cash of £29.8 million as at 30th June along with shares in US listed peer Arrowhead Pharmaceuticals (ARWR) valued at £8.56 million and which are up over 200% since Silence’s purchase."
1gw
22/9/2017
09:26
There is a material inaccuracy in that Align Research report Richie. They state the value of the Arrowhead stake as £8.56m. In fact at last nights close of $3.50 it is worth $24m or around £18m.
callumross
22/9/2017
07:54
Interesting that Align Research have put a link to their Silence update out this morning in an official RNS, entitled "Align Research updates"
1gw
22/9/2017
07:19
Note sounds very positive and is confident silence will be bought out very soon at a substantial premium.
doc robinson
22/9/2017
07:07
http://www.alignresearch.co.uk/silence-therapeutics/positive-rnai-results-silences-critics/
richie666
21/9/2017
10:43
Well this is all very nice. I thought the muted shareprice reaction to the alny news yesterday was rather strange - and but for what presumably was a very large seller feeding the buying interest I imagine we would have had a much stronger move yesterday. It will be good to see any holdings notices that come out of yesterday's volume.
1gw
21/9/2017
06:51
The recent director buys around 150p clearly aren't intended to make a 10%-20% gain. Likewise the last financing round at >200p. Everyone knows what the end game is here and I am expecting a nice steady rise up to 250-300p region ahead of the November capital markets day. Should be fun
rogen83
20/9/2017
19:46
ALNY or ARWR in would be interesting
djnzloop
20/9/2017
16:19
Wouldn't be surprised if that's Woodford out
djnzloop
20/9/2017
14:30
I've just bought some more at closer to 180 but thought I'd try to ride the "year of rnai" a bit further, having seen alny up 30% or so in the pre-market.
1gw
20/9/2017
14:13
It does seem that way. Bought a few at 170 but took awhile to execute so suspect is one seller via one broker and hence the delays? Edit: And there it is the rump 2.8m sold and off the share price goes
waterloo01
20/9/2017
14:06
I know the trade listings aren't always reliable, but given the volume going through at 170p and the spread it looks to me like there is a big supply available at 170p. i.e. an existing holder happy to sell the news and take profit at that price after the recent scare.
1gw
20/9/2017
14:00
What's the chances that any big cash influx to ALYN will lead to the suggested take out of SLN?
waterloo01
20/9/2017
13:48
A long wait of over 10 years....but great news.
benson384
20/9/2017
13:43
I think the most important aspect here, aside from any IP and licensing fees attributable to SLN is that this will be the first RNAi candidate to reach the stage of a commercial drug. This will give a huge lift to the valuations of the whole sector. Been waiting years for this.
callumross
20/9/2017
13:11
who is buying all this stock at £1.70 , they obviously want it higher, on that basis i purchased a few to trade.
partner
20/9/2017
12:39
Huge volume of automatic trades going through.
callumross
20/9/2017
12:20
Probably be announcement from SLN later re this, given the IP case in the High Court. Makes you wonder if ALNY managed the newsflow earlier this month to get the disappointing news out first leaving the Patisiran news to be announced untarnished.
callumross
20/9/2017
12:10
ALNY announces positive Patisiran results! “We are very proud to report the first ever positive Phase 3 results for an RNAi therapeutic, marking the potential arrival of an entirely new class of medicines. This moment is the culmination of a 15-year journey of tireless work by countless contributors who have overcome enormous scientific and business challenges to make RNAi therapeutics a reality,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. “This is an incredibly exciting milestone for Alnylam and RNAi, and most importantly for patients and their treating physicians and families. We extend our deepest gratitude to all the patients, investigators and study staff who participated in the APOLLO study – they made this important scientific progress possible.” ased on these positive results, Alnylam expects to file its first New Drug Application in late 2017 and first Marketing Authorisation Application shortly thereafter. Sanofi Genzyme is currently preparing for regulatory filings for patisiran in Japan, Brazil and other countries, to begin in the first half of 2018. Pending regulatory approvals, Alnylam will commercialize patisiran in the U.S., Canada and Western Europe, with Sanofi Genzyme commercializing the product in the rest of the world. “This is a significant milestone that supports our belief that RNAi therapeutics have the potential to become an innovative new class of medicines for patients with rare genetic diseases,” said Elias Zerhouni, M.D., President, Global R&D, Sanofi
callumross
Chat Pages: 2010  2009  2008  2007  2006  2005  2004  2003  2002  2001  2000  1999  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20170926 03:54:05